Stada’s Rare Kidney Disease Drug Is EU First
Germany First In Line For The Orphan Disease Drug
Stada advances its Specialty ambitions by launching the EU’s first authorized treatment for the rare kidney disease immunoglobulin A nephropathy in the form of its modified-release budesonide capsules.
You may also be interested in...
The Swedish biotech’s successful launch in the US of Tarpeyo for immunoglobulin A nephropathy is progressing well and a Chinese approval is on the horizon as partner Everest’s application is accepted by regulators.
Stada has launched abiraterone film-coated tablets, a generic version of Janssen’s Zytiga, in 21 markets across Europe as protection for the branded treatment for metastatic prostate cancer expired.
Stada and Alvotech have announced the launch of the Hukyndra higher-strength adalimumab biosimilar rival to Humira in selected European countries, with a wider roll-out to follow in the coming months.